Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received December 7, 2020
- Accepted in final form February 16, 2021
- First Published April 9, 2021.
Author Disclosures
- Leoni Rolfes, MD,
- Steffen Pfeuffer, MD (steffen.pfeuffer{at}ukmuenster.de),
- Jana Hackert, MD (jana.hackert{at}uk-essen.de),
- Marc Pawlitzki, MD (marc.pawlitzki{at}ukmuenster.de),
- Tobias Ruck, MD (tobias.ruck{at}ukmuenster.de),
- Wiebke Sondermann, MD (wiebke.sondermann{at}uk-essen.de),
- Melanie Korsen, MD (melanie.korsen{at}gmail.com),
- Heinz Wiendl, MD (heinz.wiendl{at}ukmuenster.de),
- Sven G. Meuth, MD, PhD (sven.meuth{at}uni-duesseldorf.de),
- Christoph Kleinschnitz, MD (christoph.kleinschnitz{at}uk-essen.de) and
- Refik Pul, MD (refik.pul{at}uk-essen.de)
- Leoni Rolfes, MD,
NONE
NONE
(1) Merck Serono, travel reimbursements (2) Sanofi Genzyme, travel reimbursements
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Steffen Pfeuffer, MD (steffen.pfeuffer{at}ukmuenster.de),
NONE
NONE
Commercial entity: Travel grants by Sanofi Genzyme, Merck, Biogen, Mylan
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Commercial entity: Research support from DIAMED and Merck Serono
NONE
NONE
Society: Research support from the German Multiple Sclerosis Society (DMSG)
NONE
NONE
NONE
NONE
NONE
NONE
- Jana Hackert, MD (jana.hackert{at}uk-essen.de),
NONE
NONE
(1) Celgene, travel grants, (2) Merck, honoraria for lectures and travel grants, (3) Novartis, honoraria for lectures and travel grants, (4) Roche, honoraria for lectures, (5) Sanofi Aventis, honoraria for lectures and travel grants
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marc Pawlitzki, MD (marc.pawlitzki{at}ukmuenster.de),
NONE
NONE
Novartis, funding for travel to conference 2014-2016 Merck Serono, funding for travel to conference 2017
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tobias Ruck, MD (tobias.ruck{at}ukmuenster.de),
TR served on a scientific advisory board for Genzyme, Merck and Novartis.
NONE
TR has received travel expenses from Genzyme and Novartis and has received honoraria for lecturing from Genzyme, Biogen and Teva.
Guest associate editor for Frontiers in Neurology.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
TR has received financial research support from Genzyme and Novartis.
NONE
NONE
Supported by the German Ministry of Education, Science, Research and Technology (01GI1603D, to T.R. and S.G.M.; FKZ01FI1603A to HW, LK, and CCG)
NONE
NONE
NONE
NONE
NONE
NONE
- Wiebke Sondermann, MD (wiebke.sondermann{at}uk-essen.de),
I have received personal compensation for serving on a scientific advisory board of the following commercial Entities: Novartis LEO Pharma UCB Abbvie
NONE
I have received travel expenses and/or speaker honoraria from the following commercial entities: Novartis, LEO Pharma, Sanofi Genzyme, Lilly, Janssen Cilag, Pfizer, Abbvie, UCB Type of payment: honoraria or travel expenses
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Novartis medi GmbH Bayreuth
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Melanie Korsen, MD (melanie.korsen{at}gmail.com),
NONE
NONE
Merck Serono, travel grants Biogen, travel grants
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Heinz Wiendl, MD (heinz.wiendl{at}ukmuenster.de),
(1) Biogen (2) Genzyme (3) Merck Serono (4) Novartis (5) Roche Pharma AG (6) Sanofi-Aventis
NONE
(1) Alexion (2) Biogen (3) Cognomed (4) F. Hoffmann-La Roche Ltd. (5) Gemeinnützige Hertie-Stiftung (6) Merck Serono (7) Novartis (8) Roche Pharma AG (9) Sanofi-Genzyme (10) TEVA (11) WebMD Global
(1) PLOS ONE, Editorial board member, since 2013 (2) Neurotherapeutics, since 2013 (3) Recent Patents on Inflammation & Allergy Drug Discovery
NONE
NONE
NONE
(1) Abbvie (2) Actelion (3) Argenx (4) Biogen (5) EMD (3) IGES (4) Johnson & Johnson (5) Merck (6) Novartis (7) Roche (8) Sanofi-Genzyme (9) Swiss Multiple Sclerosis Society (10)UCB
NONE
NONE
NONE
(1) Bayer Healthcare (2) Bayer Vital (3) Biogen (4) Merck Serono (5) Novartis (6) Sanofi  Genzyme (7) Sanofi US (8) TEVA Pharma
(1) German Ministry for Education and Research (BMBF), 01GI1601E, principal investigator, 2016-2019 (2)Interdisciplinary Centre of Clinical Research (IZKF) Muenster, principal investigator, 2015-2018 (4)PML Consortium, principal investigator, 2016-2018 (5) German Research Foundation, principal investigator,SFB 1009 TP A3 + SFB-TR CRC128 TP A09 + SFB TR CRC128 TP A10, TR CRC128 TP V, TR CRC128 TP Z02 2016- 2020
NONE
(1) Else Kröner Fresenius Foundation (2) Fresenius Foundation (3) Hertie Foundation (4) RE ChildrenÂs Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Sven G. Meuth, MD, PhD (sven.meuth{at}uni-duesseldorf.de),
NONE
NONE
Sven G. Meuth received honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, and Teva.
NONE
Effectivity of specific FXII/FXIIa inhibitors, especially rHA-Infestin-4, in treating neuroinflammatory diseases (WO 2013/113774 A1 und EP 2 263 110 A1) Biomarkers for diagnosis and management of neuro-immunological diseases (WO 2016/028699 A2) NR2B selective NMDA-Receptor antagonists for treatment of immune-mediated inflammatory diseases (Reference number: PCT/EP2016/069975) Detection of anti-neurochondrin autoantibody in patients with cerebellar ataxia or cerebellitis (US10,112,982B2) Diagnosis of a novel autoimmune disease (EP086120B1; US2018/0298072,A1)
NONE
NONE
NONE
NONE
NONE
NONE
SGM's research is funded by Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, Merck Serono, Novartis, ONO Pharma, Roche, and Teva
SGM's research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), German Academic Exchange Service, Interdisciplinary Center for Clinical Studies (IZKF) Muenster
NONE
SGM's research is funded by the German Foundation Neurology, Hertie Foundation, Else Kröner Fresenius Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Christoph Kleinschnitz, MD (christoph.kleinschnitz{at}uk-essen.de) and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Refik Pul, MD (refik.pul{at}uk-essen.de)
(1) Merck (2) Biogen (3) Bayer (4) Novartis
NONE
(1) Merck, funding for travel to congress, speaker honoraria (2) Biogen, speaker honararia (3) Mylan, speaker honararia (4) TEVA, speaker honararium (5) Sanofi-Genzyme, speaker honoraria
Guest Editor in Frontiers in Neurology Guest Editor in Cells
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) TEVA (2) Novartis (3) Merck (4) Sanofi-Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (L.R., S.P., M.P., T.R., H.W.), Institute of Translational Neurology, University Hospital of Münster, Germany; Department of Neurology (J.H., C.K., R.P.), University Hospital Essen, University Duisburg-Essen, Essen, Germany; Department of Dermatology (W.S.), University Hospital Essen, University Duisburg-Essen, Essen, Germany; and Department of Neurology (M.K., S.G.M.), University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Germany.
- Correspondence
Dr. Rolfes, leoni.rolfes{at}ukmuenster.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Cladribine tablets added to IFN-β in active relapsing MSThe ONWARD studyXavier Montalban, Thomas P. Leist, Bruce A. Cohen et al.Neurology: Neuroimmunology & Neuroinflammation, July 11, 2018 -
Articles
Therapeutic options in multiple sclerosisFive new thingsAugusto Miravalle, John R. Corboy et al.Neurology, November 01, 2010 -
Article
Lymphocyte counts and infection ratesLong-term fingolimod treatment in primary progressive MSEdward J. Fox, Fred D. Lublin, Jerry S. Wolinsky et al.Neurology: Neuroimmunology & Neuroinflammation, September 11, 2019 -
Updated Proceedings of the Second International Conference on the Varicella-Zoster Virus
Immunization to reduce the frequency and severity of herpes zoster and its complicationsMichael N. Oxman et al.Neurology, December 01, 1995